| 14.65 0.305 (2.13%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.45 | 1-year : | 21.55 |
| Resists | First : | 15.8 | Second : | 18.45 |
| Pivot price | 14.16  |
|||
| Supports | First : | 13.53 |
Second : | 12.14 |
| MAs | MA(5) : | 13.66 |
MA(20) : | 14.17 |
| MA(100) : | 22.52  |
MA(250) : | 26.85 |
|
| MACD | MACD : | -0.9 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 48.6 |
D(3) : | 32.2 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 35.95 | Low : | 11.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PCRX ] has closed below upper band by 37.1%. Bollinger Bands are 39.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.22 - 15.27 | 15.27 - 15.32 |
| Low: | 13.96 - 14.03 | 14.03 - 14.09 |
| Close: | 14.54 - 14.64 | 14.64 - 14.72 |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Wed, 18 Sep 2024
Renaissance Technologies LLC Buys 184,000 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Mon, 16 Sep 2024
Pacira BioSciences (NASDAQ:PCRX) Sees Strong Trading Volume - MarketBeat
Mon, 16 Sep 2024
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Mon, 09 Sep 2024
PCRX - Pacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Mon, 09 Sep 2024
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - StockTitan
Fri, 06 Sep 2024
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34% - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 46 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 116.3 (%) |
| Shares Short | 6,050 (K) |
| Shares Short P.Month | 6,310 (K) |
| EPS | 1.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.06 |
| Profit Margin | 9.2 % |
| Operating Margin | 17.3 % |
| Return on Assets (ttm) | 3.9 % |
| Return on Equity (ttm) | 7.5 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 14.96 |
| EBITDA (p.s.) | 3.8 |
| Qtrly Earnings Growth | -24.5 % |
| Operating Cash Flow | 194 (M) |
| Levered Free Cash Flow | 154 (M) |
| PE Ratio | 10.93 |
| PEG Ratio | 0.3 |
| Price to Book value | 0.76 |
| Price to Sales | 0.97 |
| Price to Cash Flow | 3.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|